 |
| |
| Mar-09-18 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$21.50 → $27 |
|
| Dec-01-17 | Resumed |
B. Riley FBR, Inc. |
Buy |
$21.50 |
|
| Nov-14-17 | Resumed |
H.C. Wainwright |
Buy |
$33 |
|
| Apr-25-17 | Initiated |
Jefferies |
Buy |
|
|
| Mar-06-17 | Reiterated |
FBR & Co. |
Outperform |
$24 → $26 |
|
| Oct-06-16 | Resumed |
Brean Capital |
Buy |
$28 |
|
| May-27-16 | Initiated |
SunTrust |
Buy |
$18 |
|
| Dec-01-15 | Initiated |
FBR Capital |
Outperform |
$29 |
|
| Sep-09-15 | Initiated |
Raymond James |
Strong Buy |
|
|
| Aug-12-15 | Resumed |
H.C. Wainwright |
Buy |
$22 |
|
| Jun-19-15 | Reiterated |
Brean Capital |
Buy |
$22 → $28 |
|
| Dec-11-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Dec-10-14 | Reiterated |
ROTH Capital |
Buy |
$25 → $33 |
|
| Oct-27-14 | Initiated |
H.C. Wainwright |
Buy |
$17 |
|
| Sep-25-14 | Reiterated |
Brean Capital |
Buy |
$19 → $22 |
|
| Jul-22-14 | Reiterated |
Brean Capital |
Buy |
$13 → $19 |
|
| Jul-02-14 | Reiterated |
MLV & Co |
Buy |
$10 → $16 |
|
| Apr-04-14 | Initiated |
Brean Capital |
Buy |
$13 |
|
| Mar-07-14 | Reiterated |
MLV & Co |
Buy |
$9 → $11 |
|
| Nov-25-13 | Reiterated |
Ladenburg Thalmann |
Buy |
$8 → $12 |
|
|
|
| Apr-20-18 08:03AM | 3 Biotech Stocks With Major Catalysts Incoming Motley Fool |
| Apr-18-18 09:00AM | TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire |
| Apr-16-18 07:00AM | Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire |
| Mar-26-18 07:30AM | TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference GlobeNewswire |
| Mar-15-18 07:30AM | TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire |
| Mar-09-18 02:21PM | Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents |
| Mar-08-18 09:36AM | TG Therapeutics reports 4Q loss Associated Press +7.87% |
| 07:30AM | TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire |
| Mar-06-18 07:30AM | TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire |
| Mar-02-18 07:30AM | TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire |
| Feb-27-18 07:07PM | Cramer's lightning round: Wall Street youngsters are weig... CNBC Videos |
| 06:50PM | Cramer's lightning round: Wall Street youngsters are weighing on oil stocks CNBC |
| 07:45AM | New Research Coverage Highlights Atkore International Group, Virtusa, Aceto, Cullen/Frost Bankers, TG Therapeutics, and Boingo Wireless Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Feb-21-18 05:18PM | Why TG Therapeutics Stock Jumped 10% Today Motley Fool +9.92% |
| 07:30AM | TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology GlobeNewswire |
| Feb-07-18 11:23AM | Harry Boxers three stocks breaking out on earnings news MarketWatch |
| Feb-05-18 08:30AM | Todays Research Reports on Trending Tickers: Array BioPharma and TG Therapeutics ACCESSWIRE |
| Feb-04-18 11:02AM | Growth Stocks Investors Love Simply Wall St. |
| 08:01AM | 3 Boom-or-Bust Biotech Stocks to Buy in 2018 Motley Fool |
| Feb-02-18 06:30AM | TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018 GlobeNewswire |
| Jan-24-18 07:30AM | TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 GlobeNewswire |
| Jan-11-18 05:02PM | Why TG Therapeutics Rallied 15.7% Today Motley Fool +15.76% |
| Jan-08-18 07:30AM | TG Therapeutics, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| 07:30AM | TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies GlobeNewswire |
| Jan-03-18 11:02AM | January Top Growth Stocks Simply Wall St. +5.71% |
| Dec-20-17 07:35AM | Market Trends Toward New Normal in TG Therapeutics, Boingo Wireless, Dave & Buster's Entertainment, Flagstar, Superior Industries International, and Benchmark Electronics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
| 07:22AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : December 20, 2017 Capital Cube |
| Dec-11-17 02:12PM | ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017 Capital Cube |
| 10:38AM | TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer? Simply Wall St. |
| 07:00AM | TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire |
| Dec-08-17 08:06AM | TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire |
| Nov-30-17 02:28PM | ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017 Capital Cube |
| Nov-29-17 08:42AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube |
| Nov-27-17 07:30AM | TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma GlobeNewswire |
| Nov-22-17 08:20AM | Todays Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics ACCESSWIRE |
| Nov-14-17 12:29PM | Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-08-17 08:03AM | TG Therapeutics reports 3Q loss Associated Press |
| 07:30AM | TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire |
| Nov-06-17 07:30AM | TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update GlobeNewswire -5.42% |
| Nov-01-17 09:30AM | TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire |
| Oct-31-17 07:30AM | TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis GlobeNewswire |
| Oct-27-17 07:30AM | TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire |
| Oct-26-17 07:30AM | TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire |
| Oct-17-17 08:10AM | Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE -9.16% |
| Oct-16-17 02:20PM | Why TG Therapeutics Is Tumbling 15% Today Motley Fool -15.68% |
| 07:30AM | TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire |
| 07:30AM | TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial GlobeNewswire |
| 07:30AM | TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire |
| Oct-12-17 08:24AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017 Capital Cube |
| Oct-05-17 07:30AM | TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development GlobeNewswire |
| Sep-29-17 08:47AM | Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX) Simply Wall St. |
| 07:30AM | TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS) GlobeNewswire |
| Sep-28-17 10:30AM | TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : September 28, 2017 Capital Cube |
| Sep-27-17 08:17AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017 Capital Cube |
| Sep-21-17 07:30AM | TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire |
| Sep-15-17 07:30AM | TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment GlobeNewswire |
| Sep-13-17 11:01AM | Should You Buy TG Therapeutics Inc (TGTX) Now? Simply Wall St. |
| Sep-05-17 07:30AM | TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire |
| Sep-01-17 07:30AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire |
| Aug-31-17 09:31PM | ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017 Capital Cube |
| Aug-24-17 10:13AM | TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube |
| Aug-14-17 08:28AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017 Capital Cube |
| Aug-13-17 02:31AM | Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents |
| Aug-10-17 07:30AM | TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial GlobeNewswire |
| Aug-09-17 01:01PM | TG Therapeutics reports 2Q loss Associated Press |
| 07:30AM | TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire |
| 05:50AM | Investor Network: TG Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-07-17 05:04PM | What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool |
| 07:30AM | TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update GlobeNewswire |
| Aug-03-17 11:37PM | TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : August 4, 2017 Capital Cube -5.88% |
| Aug-02-17 09:13AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017 Capital Cube |
| Aug-01-17 07:30AM | TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) GlobeNewswire |
| Jul-25-17 01:35PM | ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017 Capital Cube -5.81% |
| Jul-21-17 08:37AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017 Capital Cube |
| Jul-14-17 05:08PM | ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube |
| Jun-28-17 09:02AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube |
| Jun-26-17 07:30AM | TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire |
| 07:00AM | TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire |
| Jun-21-17 06:48PM | Cramer's lightning round: This defeated stock is like flypaper CNBC |
| Jun-16-17 05:45AM | TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma GlobeNewswire |
| Jun-15-17 04:21PM | New Data Shows TG Therapeutics Could Be Onto Something Big Motley Fool |
| 03:27PM | ETFs with exposure to TG Therapeutics, Inc. : June 15, 2017 Capital Cube |
| 08:00AM | Biotech Industry Showing Signs of a Revival in 2017: Today's Research on BioCryst Pharmaceuticals and TG Therapeutics Accesswire |
| 04:00AM | TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma GlobeNewswire |
| Jun-14-17 12:00PM | TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma GlobeNewswire +5.16% |
| Jun-13-17 09:29AM | Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio Motley Fool |
| 08:51AM | TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 13, 2017 Capital Cube |
| 07:30AM | TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress GlobeNewswire |
| Jun-08-17 07:30AM | TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma GlobeNewswire +5.69% |
| Jun-06-17 08:49AM | Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock? Zacks |
| 07:30AM | TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire |
| Jun-05-17 02:50PM | ETFs with exposure to TG Therapeutics, Inc. : June 5, 2017 Capital Cube -6.14% |
| 10:56AM | U.S. stocks look for direction in shadow of U.K. terror attacks MarketWatch |
| 09:43AM | Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal |
| 09:37AM | UPDATE: TG Therapeutics stock rises 4% on positive late-stage cancer trial results MarketWatch |
| 09:00AM | TG Therapeutics, Inc. Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| 08:00AM | Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire |
| Jun-03-17 06:00PM | TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
| Jun-02-17 05:37PM | Why TG Therapeutics Inc Jumped Higher Today Motley Fool +17.37% |
| 07:30AM | TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology GlobeNewswire |
|
|
|
|
| TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Power Sean A | CFO, Secretary and Treasurer | Jan 02 | Sale | 8.50 | 32,006 | 272,051 | 485,458 | Jan 03 05:25 PM | | Power Sean A | CFO, Secretary and Treasurer | Jun 19 | Sale | 11.04 | 30,000 | 331,200 | 447,464 | Jun 19 06:05 PM | | Power Sean A | CFO, Secretary and Treasurer | Jun 16 | Sale | 11.14 | 29,976 | 333,933 | 477,464 | Jun 19 06:05 PM |
|
|
|
|
|
|
